Cargando…
Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shiraz University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438341/ https://www.ncbi.nlm.nih.gov/pubmed/34539012 http://dx.doi.org/10.30476/ijms.2020.84909.1474 |
_version_ | 1783752350872109056 |
---|---|
author | Mohamadi-Zarch, Seyed-Mahdi Baluchnejadmojarad, Tourandokht Nourabadi, Davood Ramazi, Samira Nazari-Serenjeh, Morteza Roghani, Mehrdad |
author_facet | Mohamadi-Zarch, Seyed-Mahdi Baluchnejadmojarad, Tourandokht Nourabadi, Davood Ramazi, Samira Nazari-Serenjeh, Morteza Roghani, Mehrdad |
author_sort | Mohamadi-Zarch, Seyed-Mahdi |
collection | PubMed |
description | BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effects of esculetin in a mouse model of ALF. METHODS: This article is a report on an experimental study that was conducted at Iran University of Medical Sciences in 2019. Forty-eight male C57BL/6 mice were randomly divided into control, LPS/D-Gal, and LPS/D-Gal+Esculetin (40 mg/kg) groups (n=16 per group). ALF was induced with an intraperitoneal injection of lipopolysaccharide (LPS)/D-galactosamine (D-Gal).The LPS/D-Gal group received a mixture of LPS (50 μg/kg) and D-Gal (400 mg/kg). The LPS/D-Gal+Esculetin group received esculetin by gavage 24 hours and one hour before receiving LPS/D-Gal. Six hours after LPS/D-Gal injection, the mice were sacrificed. Liver injury markers, including alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), were measured in the serum. Oxidative stress indices and inflammatory markers such as interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) were measured in hepatic tissue. The histopathology of liver tissue was also assessed. The data were analyzed using one-way ANOVA, followed by the post hoc Tukey test. RESULTS: Esculetin lowered oxidative stress and myeloperoxidase activity (P<0.001); reduced the serum levels of ALT (P=0.037), AST (P=0.032), and ALP (P=0.004); and decreased the hepatic levels of IL-1β (P=0.002), IL-6 (P=0.004), toll-like receptor 4 (P<0.001), TNF-α (P=0.003), and nuclear factor-kappa B (P<0.001) as compared with LPS/D-Gal. Additionally, esculetin ameliorated hepatic tissue injury following LPS/D-Gal challenge. CONCLUSION: Esculetin can reduce liver injury through the mitigation of oxidative burden, inflammation, and neutrophil infiltration and also exerts hepatoprotective effects against ALF. |
format | Online Article Text |
id | pubmed-8438341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Shiraz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-84383412021-09-17 Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice Mohamadi-Zarch, Seyed-Mahdi Baluchnejadmojarad, Tourandokht Nourabadi, Davood Ramazi, Samira Nazari-Serenjeh, Morteza Roghani, Mehrdad Iran J Med Sci Original Article BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effects of esculetin in a mouse model of ALF. METHODS: This article is a report on an experimental study that was conducted at Iran University of Medical Sciences in 2019. Forty-eight male C57BL/6 mice were randomly divided into control, LPS/D-Gal, and LPS/D-Gal+Esculetin (40 mg/kg) groups (n=16 per group). ALF was induced with an intraperitoneal injection of lipopolysaccharide (LPS)/D-galactosamine (D-Gal).The LPS/D-Gal group received a mixture of LPS (50 μg/kg) and D-Gal (400 mg/kg). The LPS/D-Gal+Esculetin group received esculetin by gavage 24 hours and one hour before receiving LPS/D-Gal. Six hours after LPS/D-Gal injection, the mice were sacrificed. Liver injury markers, including alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), were measured in the serum. Oxidative stress indices and inflammatory markers such as interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) were measured in hepatic tissue. The histopathology of liver tissue was also assessed. The data were analyzed using one-way ANOVA, followed by the post hoc Tukey test. RESULTS: Esculetin lowered oxidative stress and myeloperoxidase activity (P<0.001); reduced the serum levels of ALT (P=0.037), AST (P=0.032), and ALP (P=0.004); and decreased the hepatic levels of IL-1β (P=0.002), IL-6 (P=0.004), toll-like receptor 4 (P<0.001), TNF-α (P=0.003), and nuclear factor-kappa B (P<0.001) as compared with LPS/D-Gal. Additionally, esculetin ameliorated hepatic tissue injury following LPS/D-Gal challenge. CONCLUSION: Esculetin can reduce liver injury through the mitigation of oxidative burden, inflammation, and neutrophil infiltration and also exerts hepatoprotective effects against ALF. Shiraz University of Medical Sciences 2021-09 /pmc/articles/PMC8438341/ /pubmed/34539012 http://dx.doi.org/10.30476/ijms.2020.84909.1474 Text en Copyright: © Iranian Journal of Medical Sciences https://creativecommons.org/licenses/by-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mohamadi-Zarch, Seyed-Mahdi Baluchnejadmojarad, Tourandokht Nourabadi, Davood Ramazi, Samira Nazari-Serenjeh, Morteza Roghani, Mehrdad Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title_full | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title_fullStr | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title_full_unstemmed | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title_short | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice |
title_sort | esculetin alleviates acute liver failure following lipopolysaccharide/d-galactosamine in male c57bl/6 mice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438341/ https://www.ncbi.nlm.nih.gov/pubmed/34539012 http://dx.doi.org/10.30476/ijms.2020.84909.1474 |
work_keys_str_mv | AT mohamadizarchseyedmahdi esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice AT baluchnejadmojaradtourandokht esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice AT nourabadidavood esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice AT ramazisamira esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice AT nazariserenjehmorteza esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice AT roghanimehrdad esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice |